V Bryan Lawlis Sells 3,750 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $74.47, for a total value of $279,262.50. Following the transaction, the director now directly owns 27,340 shares in the company, valued at $2,036,009.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NASDAQ BMRN traded down $0.33 on Thursday, reaching $75.17. The stock had a trading volume of 12,874 shares, compared to its average volume of 955,794. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.11 and a quick ratio of 2.79. The firm has a fifty day moving average of $75.31 and a two-hundred day moving average of $83.43. BioMarin Pharmaceutical Inc. has a 1-year low of $70.82 and a 1-year high of $106.74. The company has a market cap of $13.53 billion, a P/E ratio of -226.89 and a beta of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative net margin of 7.19% and a negative return on equity of 3.12%. The firm had revenue of $388.00 million during the quarter, compared to analyst estimates of $415.03 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. Research analysts predict that BioMarin Pharmaceutical Inc. will post -0.03 EPS for the current fiscal year.

BMRN has been the topic of a number of recent analyst reports. Citigroup reissued a “buy” rating on shares of BioMarin Pharmaceutical in a report on Thursday, May 23rd. Stifel Nicolaus set a $108.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Friday, September 13th. JPMorgan Chase & Co. reissued a “buy” rating and set a $133.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, August 5th. Piper Jaffray Companies set a $120.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Friday, September 13th. Finally, Wedbush reissued an “outperform” rating and set a $128.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $115.33.

Hedge funds and other institutional investors have recently modified their holdings of the business. Rational Advisors LLC grew its holdings in BioMarin Pharmaceutical by 3,211.1% in the 1st quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 289 shares in the last quarter. Doyle Wealth Management bought a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $26,000. Berman Capital Advisors LLC lifted its position in shares of BioMarin Pharmaceutical by 56.8% during the 1st quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 151 shares during the period. Twin Tree Management LP bought a new stake in shares of BioMarin Pharmaceutical during the 1st quarter valued at $36,000. Finally, Avestar Capital LLC lifted its position in shares of BioMarin Pharmaceutical by 36.9% during the 2nd quarter. Avestar Capital LLC now owns 750 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 202 shares during the period. 97.93% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Story: Why is the conference call important?

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.